ClinicalTrials.gg
CompletedNCT04445714Updated Nov 12, 2024Results posted

To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients

A Phase 4 interventional study of dapagliflozin and saxagliptin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 9 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
196
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
58th of 180
196 · median 82
Started
2021
with 11 others
Phase 4
77 of 180
7 open now
Registered
137th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 58th largest by enrollment, is one of 12 that started in 2021, is one of 77 in phase 4, and was the 137th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A prospective, multicenter, phase -IV study to assess the safety of fixed dose combination of dapagliflozin and saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients.

Read the detailed description

During the study, an AstraZeneca representative/delegate will have regular contacts with the study site, including visits to site for the site monitoring and source data verification activities. Electronic Case Report Forms (eCRF) will be used for data collection and query handling. The investigator will sign the completed electronic Case Report Forms. A copy of the completed electronic Case Report Forms will be archived at the study site. Authorized representatives of AstraZeneca or delegate, a regulatory authority, or an Ethics Committee may perform audits or inspections at the center's. Number and percentages of Incidence of adverse events will be presented, stratified by age/gender/baseline medications. Annualised event rate shall also be presented in addition to the incidence rate during the study. Mean change in HbA1C from baseline to 6 months for patients will be analysed using paired t test / Wilcoxon signed-rank test at 5% level of significance.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study subjects should fulfil the following criteria:

  1. Provision of signed and dated, written prior to any study specific procedures according to local Indian procedure.
  2. Male and female patients aged > 18 and above
  3. Documented history of type 2 diabetes mellitus with level >7.0% and ≤ 10% at screening visit
  4. Patients who are on a stable dose of antidiabetic drugs (including on Metformin dose between 1000-2000mg) in the past 3 months
  5. Female subjects must be 1 year , surgically sterile, or using an acceptable method of (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time they sign consent) to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used.

Exclusion criteria

Exclusion criteria:

  1. Known allergies or to the contents of the IP, dapagliflozin or saxagliptin tablets.
  2. Active participation in another clinical study with IP and/or device
  3. For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
  4. Type 1 diabetes mellitus.
  5. Treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors at Visit 1 or 2
  6. Patients with moderate to severe renal impairment ( persistently \<45 mL/min/1.73 m2 by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula or end-stage renal disease (ESRD) or 'Unstable or rapidly progressing renal disease
  7. Patients with severe hepatic impairment ( class C)
  8. History of pancreatitis or pancreatic surgery
  9. Patients with a history of any
  10. Patients with any of the following CV/Vascular Diseases within 3 months prior to signing the consent at enrolment, as assessed by the investigator:

    • Myocardial infarction.
    • Cardiac surgery or revascularization (CABG/PTCA).
    • Unstable angina.
    • (TIA) or significant cerebrovascular disease.
    • Unstable or previously undiagnosed arrhythmia.
  11. History of heart failure
  12. Severe uncontrolled hypertension defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg at any visit up to randomisation
  13. History of diabetic ketoacidosis
  14. Any acute/chronic systemic infections
  15. Recurrent urogenital infections
  16. Patients at risk for volume depletion as judged by the investigator
  17. Any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient or patient suspected or with confirmed poor protocol or medication compliance
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Other
    dapagliflozin and saxagliptin

    Singe arm once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally

    Drug: dapagliflozin and saxagliptin

Interventions

  • Drugdapagliflozin and saxagliptin

    Drug pages: Dapagliflozin · Saxagliptin

    Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally

    Also known as: QTERN Tablet

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs) Including Serious Adverse Events (SAEs), AEs Leading to Discontinuation (DAE), and Adverse Events of Special Interest

    Adverse events (AEs) including serious adverse events (SAEs), AEs leading to discontinuation (DAE), and adverse events of special interest (volume depletion, renal events, major hypoglycemic events, fractures, urinary/genital tract infections diabetic ketoacidosis, amputations and hospitalization for heart failure)

    Time frame: Baseline to End of Study (Week 26)

  2. Clinically Important or Significant Abnormalities in Safety Laboratory Values

    Clinical laboratory results were presented separately for haematology, clinical chemistry, and urinalysis variables. The number of participants with clinically important (haematology and clinical chemistry) or clinically significant (urinalysis) abnormalities in safety laboratory values are presented.

    Time frame: Enrolment (Week -1) to End of Study (Week 26)

  3. Clinically Important Abnormalities in ECG Values

    The number of participants with clinically important abnormalities in ECG values are presented.

    Time frame: Time Frame: Baseline to End of Study (Week 26)

  4. Clinically Important Abnormalities in Vital Signs (Pulse and Blood Pressure)

    The number of participants with clinically important abnormalities in vital signs (pulse and blood pressure).

    Time frame: Enrolment (Week -1) to End of Study (Week 26)

  5. Clinically Significant Abnormalities in Physical Examinations

    The number of participants with clinically significant abnormalities in physical examinations.

    Time frame: Enrolment (Week -1) to End of Study (Week 26)

Secondary outcomes

  1. Glycated Haemoglobin (HbA1c) Change at Week 24 Compared to Baseline

    The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring HbA1c change at week 24 compared to baseline.

    Time frame: Baseline to Week 24

  2. Weight Change at Week 24 Compared to Baseline

    The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring weight change at week 24 compared to baseline.

    Time frame: Baseline to Week 24

  3. Systolic Blood Pressure Change at Week 24 Compared to Baseline

    The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring systolic blood pressure change at week 24 compared to baseline.

    Time frame: Baseline to Week 24

  4. Fasting Plasma Glucose Change at Week 24 Compared to Baseline

    The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring fasting plasma glucose change at week 24 compared to baseline.

    Time frame: Baseline to Week 24

07

Results

Posted Nov 12, 2024

Participant flow

Participant flow — Overall Study
MilestoneFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Started196
Completed173
Not completed23
Withdrew: Discontinuation of the study14
Withdrew: High plasma glucose-fasting and hba1c; investigator decision to withdraw participant1
Withdrew: Withdrawal of informed consent8

Outcome measures

PrimaryAdverse Events (AEs) Including Serious Adverse Events (SAEs), AEs Leading to Discontinuation (DAE), and Adverse Events of Special Interest

Adverse events (AEs) including serious adverse events (SAEs), AEs leading to discontinuation (DAE), and adverse events of special interest (volume depletion, renal events, major hypoglycemic events, fractures, urinary/genital tract infections diabetic ketoacidosis, amputations and hospitalization for heart failure)

Time frame:
Baseline to End of Study (Week 26)
Reported as:
Number · events
Adverse Events (AEs) Including Serious Adverse Events (SAEs), AEs Leading to Discontinuation (DAE), and Adverse Events of Special Interest
eventsFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
AEs40
SAEs0
DAEs0
Adverse events of special interest4
PrimaryClinically Important or Significant Abnormalities in Safety Laboratory Values

Clinical laboratory results were presented separately for haematology, clinical chemistry, and urinalysis variables. The number of participants with clinically important (haematology and clinical chemistry) or clinically significant (urinalysis) abnormalities in safety laboratory values are presented.

Time frame:
Enrolment (Week -1) to End of Study (Week 26)
Reported as:
Count of participants · Participants
Clinically Important or Significant Abnormalities in Safety Laboratory Values
ParticipantsFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Clinically Important or Significant Abnormalities in Safety Laboratory Values0
PrimaryClinically Important Abnormalities in ECG Values

The number of participants with clinically important abnormalities in ECG values are presented.

Time frame:
Time Frame: Baseline to End of Study (Week 26)
Reported as:
Count of participants · Participants
Clinically Important Abnormalities in ECG Values
ParticipantsFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Clinically Important Abnormalities in ECG Values0
PrimaryClinically Important Abnormalities in Vital Signs (Pulse and Blood Pressure)

The number of participants with clinically important abnormalities in vital signs (pulse and blood pressure).

Time frame:
Enrolment (Week -1) to End of Study (Week 26)
Reported as:
Count of participants · Participants
Clinically Important Abnormalities in Vital Signs (Pulse and Blood Pressure)
ParticipantsFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Clinically Important Abnormalities in Vital Signs (Pulse and Blood Pressure)0
PrimaryClinically Significant Abnormalities in Physical Examinations

The number of participants with clinically significant abnormalities in physical examinations.

Time frame:
Enrolment (Week -1) to End of Study (Week 26)
Reported as:
Count of participants · Participants
Clinically Significant Abnormalities in Physical Examinations
ParticipantsFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Clinically Significant Abnormalities in Physical Examinations0
SecondaryGlycated Haemoglobin (HbA1c) Change at Week 24 Compared to Baseline

The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring HbA1c change at week 24 compared to baseline.

Time frame:
Baseline to Week 24
Reported as:
Mean · percentage of glycated haemoglobin
Glycated Haemoglobin (HbA1c) Change at Week 24 Compared to Baseline
percentage of glycated haemoglobinFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Baseline (Visit 2)8.6 ± 0.77
Week 247.4 ± 0.98
Change from Baseline-1.2 ± 1.09
Statistical analysis
  • Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg · Paired t-test test · p = <.0001 · Mean difference (final values): -1.2 · 95% CI -1.34 to -1.03
SecondaryWeight Change at Week 24 Compared to Baseline

The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring weight change at week 24 compared to baseline.

Time frame:
Baseline to Week 24
Reported as:
Mean · kilograms
Weight Change at Week 24 Compared to Baseline
kilogramsFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Baseline (Visit 2)74.2 ± 12.59
Week 2472.2 ± 11.51
Change from Baseline-2.1 ± 3.98
Statistical analysis
  • Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg · Paired t-test test · p = <.0001 · Mean difference (final values): -2.1 · 95% CI -2.66 to -1.51
SecondarySystolic Blood Pressure Change at Week 24 Compared to Baseline

The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring systolic blood pressure change at week 24 compared to baseline.

Time frame:
Baseline to Week 24
Reported as:
Mean · mmHg
Systolic Blood Pressure Change at Week 24 Compared to Baseline
mmHgFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Baseline (Visit 2)125.7 ± 9.27
Week 24124.5 ± 10.33
Change from Baseline-0.2 ± 12.90
Statistical analysis
  • Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg · Paired t-test test · p = 0.8416 · Mean difference (final values): -0.2 · 95% CI -2.34 to 1.91
SecondaryFasting Plasma Glucose Change at Week 24 Compared to Baseline

The efficacy of the fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus participants was analyzed by measuring fasting plasma glucose change at week 24 compared to baseline.

Time frame:
Baseline to Week 24
Reported as:
Mean · mg/dL
Fasting Plasma Glucose Change at Week 24 Compared to Baseline
mg/dLFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Baseline (Visit 2)161.8 ± 52.30
Week 24136.7 ± 41.98
Change from Baseline-24.4 ± 62.89
Statistical analysis
  • Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg · Paired t-test test · p = <.0001 · Mean difference (final values): -24.4 · 95% CI -33.4 to -15.4

Adverse events

Collected over Week 0 to End of Study (26 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg0/196 (0%)0/196 (0%)22/196 (11.2%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventFixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mg
Urinary tract infectionInfections and infestations5/196
PyrexiaGeneral disorders5/196
NasopharyngitisInfections and infestations3/196
BalanoposthitisReproductive system and breast disorders3/196
NauseaGastrointestinal disorders2/196
VomitingGastrointestinal disorders2/196
HypersensitivityImmune system disorders1/196
Balanitis candidaInfections and infestations1/196
PharyngitisInfections and infestations1/196
TrichomoniasisInfections and infestations1/196

Baseline characteristics

Enrolled population

Age, Continuous
Age, Continuous(Years)Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall
Mean52.2 ± 10.27
Sex: Female, Male
Sex: Female, Male(Participants)Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall
Female76
Male120
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall
American Indian or Alaska Native0
Asian196
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Height
Height(centimeters)Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall
Mean163 ± 8.62
Weight
Weight(kilograms)Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall
Mean74.2 ± 12.59
Waist circumference
Waist circumference(centimeters)Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall
Mean97.5 ± 12.76
Body mass index
Body mass index(kg/m^2)Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall
Mean28.0 ± 4.35
Glycated haemoglobin
Glycated haemoglobin(percentage of glycated haemoglobin)Fixed Dose Combination of Dapagliflozin 10 mg / Saxagliptin 5 mgOverall
Mean8.6 ± 0.77

2 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Research Site
    Bangalore, 560017, India
  • Research Site
    Bhubaneswar, 751007, India
  • Research Site
    Chandigarh, 160012, India
  • Research Site
    Coimbatore, 641018, India
  • Research Site
    Hyderabad, 500024, India
  • Research Site
    Kolkata, 700020, India
  • Research Site
    Lucknow, 226003, India
  • Research Site
    Mohali, 160062, India
  • Research Site
    New Delhi, 110076, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.'

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Mar 2023, 23 months.

Results were first posted in Nov 2024, 1 year 7 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 23 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2020
First posted
Jun 24, 2020
StartActual
Apr 7, 2021
Primary completionActual
Mar 14, 2023
CompletionActual
Mar 14, 2023
Results first posted
Nov 12, 2024
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04445714
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 24, 2020
Start date
Apr 7, 2021
Primary completion
Mar 14, 2023
Completion
Mar 14, 2023
Results posted
Nov 12, 2024
Last update
Nov 12, 2024

Study contacts

Dr Anil Bhansali
principal investigator · Post Graduate Institute of Medical Education and Research, Chandigarh
Dr K P Singh
principal investigator · Fortis Hospital Mohali
Dr Indira Pattnaik
principal investigator · Sparsh Hospitals & Critical Care (P) Ltd, Bhubaneswar
Dr Sandeep Kumar Gupta
principal investigator · M V Hospital &Research centre Lucknow
Dr Faraz Farishta
principal investigator · Thumbay Hospital New Life Hyderabad
Dr Girithara Jayaram Naidu
principal investigator · KG Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Saxagliptin

Start the discussion